
Home » Gala Therapeutics Earns CE Mark for Chronic Bronchitis Treatment
Gala Therapeutics Earns CE Mark for Chronic Bronchitis Treatment
Gala Therapeutics’ RheOx system has received the CE Mark for treating patients with chronic bronchitis, a type of chronic obstructive pulmonary disease (COPD) in which the inflamed bronchial tubes create excessive mucus.
The device is used in a minimally invasive procedure called Bronchial Rheoplasty, in which it gives off non-thermal energy to the airways to reduce mucus-producing cells.
The company said it now plans to begin a postmarket study at key European respiratory centers to increase clinician experience with the procedure and device.
Upcoming Events
-
28Sep
-
28Sep
-
11Oct
-
16Oct
-
26Oct
-
02Nov